Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
GLP-1 and Fatty Liver Disease (NAFLD/NASH) GLP-1RAs show promising benefits in: Hepatic steatosis reduction Weight loss-mediated liver improvement Improved insulin resistance Reduced inflammation These agents are likely to become central therapies in metabolic-associated steatotic liver disease (MASLD)
NCT06015893 Semaglutide Therapy for Alcohol Reduction (STAR) Status: Recruiting This study will test the safety/tolerability and early efficacy of subcutaneous (s.c.) semaglutide at the dose of 2.4 mg/week or maximum tolerated dose (MTD) as a potential new treatment for alcohol use disorder (AUD)
Is 5-Amino-1MQ like a GLP-1 (e.g., semaglutide)
Its potent antioxidant qualities shield skin cells from oxidative stress, which can hasten the aging process (5)
